Background: Several qPCR kits are available for SARS-CoV-2 diagnosis, mostly lacking of evaluation due to covid19 emergency.
Objective: We evaluated nCoV-QS (MiCo BioMed) kit using CDC kit as gold standard.
Results: We found limitations for nCoV-QS: 1) lower sensitivity 2) lack of RNA quality control probe.
Conclusions: Validation studies should be implemented for any SARS-CoV-2 RT-qPCR commercial kit to prevent unreliable diagnosis.
Keywords: CDC; RT-qPCR; SARS-CoV-2; Validation.
Copyright © 2020 Elsevier B.V. All rights reserved.